Elicio Therapeutics Stock Price Patterns
| ELTX Stock | 8.84 0.04 0.45% |
Momentum 46
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter (0.35) | EPS Estimate Current Year (2.50) | EPS Estimate Next Year (1.50) | Wall Street Target Price 15.5 | EPS Estimate Current Quarter (0.48) |
Using Elicio Therapeutics hype-based prediction, you can estimate the value of Elicio Therapeutics from the perspective of Elicio Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Elicio Therapeutics using Elicio Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Elicio using crowd psychology based on the activity and movement of Elicio Therapeutics' stock price.
Elicio Therapeutics Implied Volatility | 2.33 |
Elicio Therapeutics' implied volatility exposes the market's sentiment of Elicio Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Elicio Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Elicio Therapeutics stock will not fluctuate a lot when Elicio Therapeutics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Elicio Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Elicio because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Elicio Therapeutics after-hype prediction price | USD 8.78 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Elicio contract
Based on the Rule 16, the options market is currently suggesting that Elicio Therapeutics will have an average daily up or down price movement of about 0.15% per day over the life of the 2026-05-15 option contract. With Elicio Therapeutics trading at USD 8.84, that is roughly USD 0.0129 . If you think that the market is fully incorporating Elicio Therapeutics' daily price movement you should consider acquiring Elicio Therapeutics options at the current volatility level of 2.33%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out Elicio Therapeutics Basic Forecasting Models to cross-verify your projections. Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Elicio Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Elicio Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Elicio Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Elicio Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Elicio Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Elicio Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Elicio Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Elicio Therapeutics' historical news coverage. Elicio Therapeutics' after-hype downside and upside margins for the prediction period are 4.37 and 13.19, respectively. We have considered Elicio Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Elicio Therapeutics is somewhat reliable at this time. Analysis and calculation of next after-hype price of Elicio Therapeutics is based on 3 months time horizon.
Elicio Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Elicio Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Elicio Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Elicio Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.17 | 4.37 | 0.00 | 0.00 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
8.84 | 8.78 | 0.00 |
|
Elicio Therapeutics Hype Timeline
Elicio Therapeutics is currently traded for 8.84. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Elicio is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is currently at 0.17%. %. The volatility of related hype on Elicio Therapeutics is about 20809.52%, with the expected price after the next announcement by competition of 8.84. About 37.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.11. Elicio Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 2nd of June 2023. Given the investment horizon of 90 days the next anticipated press release will be in about 8 days. Check out Elicio Therapeutics Basic Forecasting Models to cross-verify your projections.Elicio Therapeutics Related Hype Analysis
Having access to credible news sources related to Elicio Therapeutics' direct competition is more important than ever and may enhance your ability to predict Elicio Therapeutics' future price movements. Getting to know how Elicio Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Elicio Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| APLT | Applied Therapeutics | 0.00 | 9 per month | 0.00 | (0.20) | 10.00 | (15.73) | 83.66 | |
| CRBP | Corbus Pharmaceuticals Holding | (0.09) | 10 per month | 0.00 | (0.18) | 4.60 | (6.85) | 15.41 | |
| MOLN | Molecular Partners AG | 0.27 | 7 per month | 2.48 | 0.07 | 4.73 | (3.57) | 14.54 | |
| CRDF | Cardiff Oncology | 0.26 | 10 per month | 0.00 | (0.06) | 9.28 | (6.82) | 45.59 | |
| RANI | Rani Therapeutics Holdings | (0.01) | 4 per month | 0.00 | (0.14) | 7.04 | (7.56) | 26.23 | |
| MIST | Milestone Pharmaceuticals | (0.06) | 10 per month | 0.00 | (0.04) | 5.67 | (6.38) | 34.31 | |
| PEPG | PepGen | 0.18 | 8 per month | 5.91 | 0.08 | 12.87 | (10.09) | 27.05 | |
| NKTX | Nkarta Inc | (0.03) | 7 per month | 3.18 | 0.06 | 6.74 | (5.96) | 17.73 | |
| SAVA | Cassava Sciences | (0.12) | 6 per month | 0.00 | (0.1) | 9.05 | (7.56) | 35.02 | |
| ACTU | Actuate Therapeutics Common | (0.61) | 6 per month | 0.00 | (0.13) | 6.79 | (8.67) | 20.01 |
Elicio Therapeutics Additional Predictive Modules
Most predictive techniques to examine Elicio price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Elicio using various technical indicators. When you analyze Elicio charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Elicio Therapeutics Predictive Indicators
The successful prediction of Elicio Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Elicio Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Elicio Therapeutics based on analysis of Elicio Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Elicio Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Elicio Therapeutics's related companies. | 2025 | 2026 (projected) | Interest Debt Per Share | 2.5 | 2.37 | Revenue Per Share | 10.17 | 9.67 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Elicio Stock Analysis
When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.